A real-time polymerase chain reaction assay for rapid, sensitive, and specific quantification of the JAK2V617F mutation using a locked nucleic acid-modified oligonucleotide

Journal of Molecular Diagnostics

Volumn 12, Issue 4, 2010, Pages 512-519

  Denys, Barbara ^a   El Housni, Hakim ^b   Nollet, Friedel ^c   Verhasselt, Bruno ^a   Philippé, Jan ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c Laboratory of Hematology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; NUCLEIC ACID; OLIGONUCLEOTIDE; LOCKED NUCLEIC ACID;

ACCURACY; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DILUTION; EMBRYO; HUMAN; HUMAN CELL; HYDROLYSIS; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MUTATION; PERFORMANCE; POLYCYTHEMIA VERA; REAL TIME POLYMERASE CHAIN REACTION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; THROMBOCYTHEMIA; WILD TYPE; ALLELE; AMINO ACID SUBSTITUTION; BIOASSAY; GENETICS; GENOTYPE; METABOLISM; POLYMERASE CHAIN REACTION; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TIME;

ALLELES; AMINO ACID SUBSTITUTION; BIOLOGICAL ASSAY; GENOTYPE; HUMANS; JANUS KINASE 2; MUTATION; OLIGONUCLEOTIDES; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 77954373565     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2010.090137     Document Type: Article

References (41)

1. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C: The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 2008, 87:1-10 (Pubitemid 50003807)
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148 (Pubitemid 40663494)
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790 (Pubitemid 40570926)
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061
5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397
6. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097
7. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2008
8. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A: Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008, 22:1299-1307
9. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V, Longo G, Bosi A, Vannucchi AM: Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005, 19: 1847-1849
10. Tefferi A: JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008, 49:388-397
11. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Gerli G, Specchia G, Tinelli C, Rambaldi A, Barbui T: JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007, 110:4030-4036
12. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T: Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110:840-846 (Pubitemid 47267419)
13. Scott LM, Scott MA, Campbell PJ, Green AR: Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006, 108:2435-2437
14. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T: Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007, 21:1952-1959
15. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM: Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008, 93:41-48
16. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC: The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol 2007, 79:508-515 (Pubitemid 350126669)
17. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Li CY, Wu W, Ketterling RP, Pardanani A, Tefferi A: Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007, 109:2279-2284 (Pubitemid 46801558)
18. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC: Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008, 111:3931-3940
19. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, Wu W, Hanson CA, Pardanani A: Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008, 22:756-761
20. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo G, Ammatuna E, Liso V, Bosi A, Barbui T, Vannucchi AM: Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009, 114:1477-1483
21. Pardanani A: JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008, 22:23-30
22. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162-2168
23. Steensma DP: JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006, 8:397-411; quiz 526
24. Sutton BC, Allen RA, Zhao ZJ, Dunn ST: Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark 2007, 3:315-324 (Pubitemid 350192855)
25. McClure R, Mai M, Lasho T: Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006, 20:168-171
26. Frantz C, Sekora DM, Henley DC, Huang CK, Pan Q, Quigley NB, Gorman E, Hubbard RA, Mirza I: Comparative evaluation of three JAK2V617F mutation detection methods. Am J Clin Pathol 2007, 128:865-874 (Pubitemid 350134000)
27. Tan AY, Westerman DA, Dobrovic A: A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. Am J Clin Pathol 2007, 127:977-981
28. Murugesan G, Aboudola S, Szpurka H, Verbic MA, Maciejewski JP, Tubbs RR, Hsi ED: Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006, 125:625-633
29. Olsen RJ, Tang Z, Farkas DH, Bernard DW, Zu Y, Chang CC: Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med 2006, 130:997-1003 (Pubitemid 44061430)
30. Chen Q, Lu P, Jones AV, Cross NC, Silver RT, Wang YL: Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn 2007, 9:272-276 (Pubitemid 47305096)
31. Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M, Reiter A, Zabelina T, Zander AR, Fehse B: Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109:1316-1321
32. Wolstencroft EC, Hanlon K, Harries LW, Standen GR, Sternberg A, Ellard S: Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation. J Mol Diagn 2007, 9:42-46
33. Hammond E, Shaw K, Carnley B, P'ng S, James I, Herrmann R: Quantitative determination of JAK2 V617F by TaqMan: an absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. J Mol Diagn 2007, 9:242-248
34. Poodt J, Fijnheer R, Walsh IB, Hermans MH: A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. Hematol Oncol 2006, 24:227-233
35. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N: The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007, 136:745-751
36. Sidon P, Heimann P, Lambert F, Dessars B, Robin V, El Housni H: Combined locked nucleic acid and molecular beacon technologies for sensitive detection of the JAK2V617F somatic single-base sequence variant. Clin Chem 2006, 52:1436-1438
37. Latorra D, Campbell K, Wolter A, Hurley JM: Enhanced allele-specific PCR discrimination in SNP genotyping using 3′ locked nucleic acid (LNA) primers. Hum Mutat 2003, 22:79-85
38. Jaffe ES, Harris NL, Stein H, Vardiman JW: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001
39. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kroger N, Herrmann R, Prchal JT, Skoda RC, Hermouet S: Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2009, 94:38-45
40. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG: JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006, 20:471-476
41. Hermouet S, Dobo I, Lippert E, Boursier MC, Ergand L, Perrault-Hu F, Pineau D: Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F). Leukemia 2007, 21:1128-1130 (Pubitemid 46672099)